A phase 1, double-blind dose-escalation study of the safety and pharmacokinetics of xoma 3B VS placebo administered intravenously in healthy adults
Ended Awarded Last action
- Contract number
- HHSN27200013
- Awardee
-
Duke University UEI TP7EK8DZV6N5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,748,121
Award facts
- Opportunity
-
- NIAIDDMIDNIHAI2012144 Solicitation number
- Vaccine and treatment evaluation units (vteu) Award Notice · Posted Mar 29, 2012
- Contract value 100% obligated
- $2,748,120.58 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Durham, NC 27705, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$332,059 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $42,858 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $568,132 | |
| Other Administrative Action | $0 | |
| Change Order | $896,652 | |
| Original award | $1,572,538 |
About this award
This federal contract award, with a ceiling value of $2,748,120.58, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) to Duke University. The contract is a Delivery Order under the Vaccine and Treatment Evaluation Units (VTEU) indefinite delivery vehicle (IDV). The purpose of the contract is to conduct a Phase 1, double-blind, dose-escalation study of the safety and pharmacokinetics of XOMA 3B versus placebo administered intravenously in healthy adults. The contract does not have a set-aside designation. As a top-ranked research university, Duke University has been awarded numerous federal contracts and grants to provide a diverse array of services to government agencies, including clinical research, biomedical studies, and advanced technological development.
Quick answers
Who was awarded contract HHSN27200013?
HHSN27200013 was awarded to Duke University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on December 1, 2015.
How much is contract HHSN27200013 worth?
The government has obligated $2,748,121 on HHSN27200013.
Is contract HHSN27200013 an order under another contract?
Yes. HHSN27200013 is a delivery order under HHSN272201300017I, an indefinite delivery contract, on Vaccine and Treatment Evaluation Units (VTEU).
Was contract HHSN27200013 competed?
The extent of competition for HHSN27200013 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award